Hypertonic saline resuscitation: A tool to modulate immune function in trauma patients?

Shock

Volumn 8, Issue 4, 1997, Pages 235-241

  Junger, Wolfgang G ^a   Coimbra, Raul ^a   Liu, Forrest C ^a   Herdon Remelius, Crystal ^a   Junger, Werner ^a   Junger, Heidi ^a   Loomis, William ^a   Hoyt, David B ^a   Altman, Amnon ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; SODIUM CHLORIDE;

ANIMAL; HUMAN; IMMUNOLOGY; INJURY; METHODOLOGY; RESUSCITATION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; RESUSCITATION; SALINE SOLUTION, HYPERTONIC; WOUNDS AND INJURIES;

EID: 0031253697     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199710000-00001     Document Type: Article

References (44)

1. Velasco IT, Pontieri V, Roche e Silva M, Lopes OU: Hyperosmotic NaCl and severe hemorrhagic shock. Am J Physiol 239:H664-H673, 1980.
2. Mattox KL, Maningas PA, Moore EE, et al: Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. multicenter trial. Ann Surg 213:482-491, 1991.
3. Kramer GC, Poli de Figueiredo LF, Elgjo GI, Wade CE: Systemic mechanisms and clinical experiences with small volume hypertonic resuscitation. Int J Microcirc 16:25, 1996.
4. Rowe GG, McKenna DH, Corliss RJ, Sialer S: Hemodynamic effects of hypertonic sodium chloride. J Appl Physiol 32:182-184, 1972.
5. Traverso LW, Bellamy RF, Hollenbach SJ, Witcher LD: Hypertonic sodium chloride solutions: Effect on hemodynamics and survival after hemorrhage in swine. J Trauma 27:32-39, 1987.
6. Bitterman H, Triolo J, Lefer AM: Use of hypertonic saline in the treatment of hemorrhagic shock. Circ Shock 21:271-283, 1987.
7. Suzuki K, Ogino R, Nishina M, Kohama A: Effects of hypertonic saline and dextran 70 on cardiac functions after bums. Am J Physiol 268:H856-H864, 1995.
8. Junger WG, Liu FC, Loomis WH, Hoyt DB: Hypertonic saline enhances cellular immune function. Circ Shock 42:190-196, 1994.
9. Alexander JW, Moncrief JA: Alterations of the immune response following severe thermal injury. Arch Surg 93:75-83, 1966.
10. Wolfe JHN, Wu AVO, O'Connor NE, Saporoschetz I, Mannick JA: Anergy, immunosuppressive serum, and impaired lymphocyte blastogenesis in bum patients. Arch Surg 117:1266-1271, 1982.
11. O'Mahoney JB, Palder SB, Wood JJ, McIrvine A, Roderick ML, Demling RH, Mannick JA: Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma 24:869-875, 1984.
12. Ozkan AN, Tompkins S, Gregory S, Hoyt DB: Immunologic mechanisms of a trauma associated glycopeptide. J Leukocyte Biol 44:300-308, 1988.
13. Chaudry IH, Ayala A: Immunological Aspects of Hemorrhage. Austin, TX: RG Landes Company, 1992, pp 1-132.
14. Junger WG, Hoyt DB, Liu FC, Loomis WH, Coimbra R: Immunosuppression following endotoxin shock: The result of multiple anti-inflammatory factors. J Trauma 40:702-709, 1996.
15. Baker CC, Oppenheimer L, Lewis FR, Trunkey DD: The epidemiology of trauma death. Am J Surg 140:144-150, 1980.
16. Ota IM, Varshavsky A: A yeast protein similar to bacterial two-component regulators. Science 262:566-569, 1993.
17. Brewster JL, de Valoir T, Dwyer ND, Winter E, Gustin MC: An osmosensing signal transduction pathway in yeast. Science 259:1760-1763, 1993.
18. Maeda T, Wurgler-Murphy SM, Saito H: A two-component system that regulates an osmosensing MAP kinase cascade in yeast. Nature 369:242-245, 1994.
19. Maeda T, Takekawa M, Saito H: Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor. Science 269:554-558, 1995.
20. Han J, Lee J-D, Bibbs L, Ulevitch RJ: A MAP kinase target by endotoxin and hyperosmolality in mammalian cells. Science 265:808-811, 1994.
21. Galcheva-Gargova Z, Derijard B, Wu I-H, Davis RJ: An osmosensing signal transduction pathway in mammalian cells. Science 265:806-808, 1994.
22. Hunter T: Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 80:225-236, 1995.
23. Junger WG, Hoyt DB, Liu FC, Junger W, Loomis WH: Hypertonic saline activates T-cell signaling events. J Trauma 41:189, 1996.
24. Junger WG, Hoyt DB, Liu FC, Junger W, Loomis WH: Hypertonic saline activates protein tyrosine kinases and mitogen-activated protein kinase p 38 in T-cells. J Trauma 42:437-445, 1997.
25. Cano E, Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20:117-122, 1995.
26. Raingeaud J, Gupta S, Rogers JS, et al: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270:7420-7426, 1995.
27. Novogrodsky A, Patya M, Avissar S, Stenzel KH: Osmotic enhancement of mitogen stimulation in PNA-negative murine thymocytes. Cell Immunol 105:262-269, 1987.
28. Shapiro L, Dinarello CA: Osmotic regulation of cytokine synthesis in vitro. Proc Natl Acad Sci USA 92:12230-12234, 1995.
29. Miller-Graziano CL, Szabo G, Griffey K, Mehta B, Kodys K, Catalano D: Role of elevated monocyte transforming growth factor β (TGF/β) production in posttrauma immunosuppression. J Clin Immunol 11:95-104, 1991.
30. 2 production in severely injured patients. Arch Surg 123:293-301, 1988.
31. 2. J Immunol 145:2616-2624, 1990.
32. 2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J Exp Med 178:1813-1817, 1993.
33. 2)-induced T-cell suppression. Shock 4:45-49, 1995.
34. Gaspari AA, Katz SI: Contact hypersensitivity. In Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM, Strober W (eds): Current Protocols in Immunology. New York: Greene Publishing & Wiley-Interscience, 1995, pp 4.2.1.
35. 2 and interleukin-4 production. J Surg Res 64:203-209, 1995.
36. Wahl SM, Hunt DA, Wong HL, et al: Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 140:3026-3033, 1988.
37. Martinez OM, Gibbons RS, Garovoy MR, Aronson FR: IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T-cells. J Immunol 144:2211-2219, 1990.
38. Taga K, Tosato G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148:1143-1149, 1992.
39. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes. J Biol Chem 270:9558-9563, 1995.
40. Coimbra R, Hoyt DB, Junger WG, et al: Hypertonic saline resuscitation decreases susceptibility to sepsis following hemorrhagic shock. J Trauma 42:602-606, 1997.
41. Wiessner WH, Casey LC, Zbilut JP: Treatment of sepsis and septic shock: A review. Heart Lung 24:380-392, 1995.
42. Suffredini AF: Current prospects for the treatment of clinical sepsis. Crit Care Med 22:S12-S18, 1994.
43. Vassar MJ, Fischer RP, O'Brien PE, et al: A multicenter trial for resuscitation of injured patients with 7.5% sodium chloride. The effect of added dextran 70. The Multicenter Group for the Study of Hypertonic Saline in Trauma Patients. Arch Surg 128:1003-1013, 1993.
44. Vassar MJ, Perry CA, Holcroft JW: Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl versus 7.5% NaCl with added dextran: A controlled trial. J Trauma 34:622-633, 1993.